Booming US Generic Drug Market
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00
The US represents one of the world’s largest economies. The countries per capita income and spending are rated among the highest in the world. On the back of rapidly growing consumer spending on branded products, the US healthcare spending is projected to reach nearly US$ 4.6 Trillion by 2019 at an average annual rate of 6.3%. The government is now emphasizing to minimize the healthcare spending by using generics drugs and promoting other low cost healthcare. This has created huge opportunities in the country’s generics industry.
The US generics market is anticipated to grow at a CAGR of around 10% during 2010-2013, says our recent research report “Booming US Generic Drug Market”. Currently, the market growth is largely fuelled by the emergence of new products as patents of branded drugs are getting expired, and the trend is likely to continue over the next 3-4 years. Anticipating the future growth, big pharma players are making deals with some generics manufactures from the Asian countries, like India, to access their products and market them in the US. This trend will emerge more strongly during our forecast period, providing opportunities for the local players to widen their product portfolios.
Although several challenges such as price erosion and litigations from branded manufacturers may hamper the growth, the overall growth prospects of the market remain good. In this regard, our report provides rational analysis of various factors which will drive the generics market in the US over the forecast period.
The report also provides extensive information of the US generics market, discusses the emerging trends like injectable generics, anti-counterfeit coalition. Thus, it provides valuable information to pharmaceutical & generics companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00
The US represents one of the world’s largest economies. The countries per capita income and spending are rated among the highest in the world. On the back of rapidly growing consumer spending on branded products, the US healthcare spending is projected to reach nearly US$ 4.6 Trillion by 2019 at an average annual rate of 6.3%. The government is now emphasizing to minimize the healthcare spending by using generics drugs and promoting other low cost healthcare. This has created huge opportunities in the country’s generics industry.
The US generics market is anticipated to grow at a CAGR of around 10% during 2010-2013, says our recent research report “Booming US Generic Drug Market”. Currently, the market growth is largely fuelled by the emergence of new products as patents of branded drugs are getting expired, and the trend is likely to continue over the next 3-4 years. Anticipating the future growth, big pharma players are making deals with some generics manufactures from the Asian countries, like India, to access their products and market them in the US. This trend will emerge more strongly during our forecast period, providing opportunities for the local players to widen their product portfolios.
Although several challenges such as price erosion and litigations from branded manufacturers may hamper the growth, the overall growth prospects of the market remain good. In this regard, our report provides rational analysis of various factors which will drive the generics market in the US over the forecast period.
The report also provides extensive information of the US generics market, discusses the emerging trends like injectable generics, anti-counterfeit coalition. Thus, it provides valuable information to pharmaceutical & generics companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. INDUSTRY PERFORMANCE AND FORECAST TO 2013
4.1 Branded vs Generics
4.2 Generic Drugs Market
4.2.1 By Value
4.2.2 By Volume
5. MARKET POTENTIAL OF GENERIC DRUGS IN KEY THERAPIES SEGMENTS
5.1 Lipid Regulators
5.2 Antipsychotics
5.3 Angiotensin II Receptor
5.4 Anti Depressants
5.5 Human Insulin
5.6 Proton Pump Inhibitors
5.7 Erythropoietin
6. REGULATORY ENVIRONMENT
6.1 Drug Efficacy Study Implementation (DESI) Program
6.2 Hatch-Waxman Act
6.3 Patent Infringement Litigations
6.4 Para IV & the 180-day Marketing Exclusivity
6.5 FDA Requirements
6.6 Generic Initiative for Value & Efficiency (GIVE)
6.7 Healthcare Bill 2010
6.8 Ban on “Pay for delay” Settlements
6.9 Patient Protection and Affordable Care Act
7. EMERGING MARKET TRENDS
7.1 Biogenerics/Biosimilar
7.2 Anti-counterfeit Coalition
7.3 Injectable Generics
7.4 Patent Expiration
8. KEY PLAYERS
8.1 Teva Pharmaceuticals USA
8.2 Watson Pharmaceuticals, Inc.
8.3 Mylan Laboratories Inc.
8.4 Pfizer Inc.
8.5 Sandoz Inc. (Novartis)
2. RESEARCH METHODOLOGY
3. MARKET OVERVIEW
4. INDUSTRY PERFORMANCE AND FORECAST TO 2013
4.1 Branded vs Generics
4.2 Generic Drugs Market
4.2.1 By Value
4.2.2 By Volume
5. MARKET POTENTIAL OF GENERIC DRUGS IN KEY THERAPIES SEGMENTS
5.1 Lipid Regulators
5.2 Antipsychotics
5.3 Angiotensin II Receptor
5.4 Anti Depressants
5.5 Human Insulin
5.6 Proton Pump Inhibitors
5.7 Erythropoietin
6. REGULATORY ENVIRONMENT
6.1 Drug Efficacy Study Implementation (DESI) Program
6.2 Hatch-Waxman Act
6.3 Patent Infringement Litigations
6.4 Para IV & the 180-day Marketing Exclusivity
6.5 FDA Requirements
6.6 Generic Initiative for Value & Efficiency (GIVE)
6.7 Healthcare Bill 2010
6.8 Ban on “Pay for delay” Settlements
6.9 Patient Protection and Affordable Care Act
7. EMERGING MARKET TRENDS
7.1 Biogenerics/Biosimilar
7.2 Anti-counterfeit Coalition
7.3 Injectable Generics
7.4 Patent Expiration
8. KEY PLAYERS
8.1 Teva Pharmaceuticals USA
8.2 Watson Pharmaceuticals, Inc.
8.3 Mylan Laboratories Inc.
8.4 Pfizer Inc.
8.5 Sandoz Inc. (Novartis)
LIST OF FIGURES:
Figure 4-1: Share of Branded and Generic Drugs in Prescription Market (2008 & 2009)
Figure 4-2: Generic Drugs Market (Billion US$) 2009-2013
Figure 4-3: Share of Generic and Branded Drugs in Pharma Market (By Sales Value), 2009
Figure 4-4: Share of Generic and Branded Drugs in Prescription Market (By Sales Volume), 2009
Figure 6-1: Generic Drugs Approval Process
Figure 7-1: US - Biogenerics Market (Billion US$), 2008 & 2013
Figure 7-2: Forecast for Share of Drugs Type in Biogenerics Market (2016)
Figure 4-1: Share of Branded and Generic Drugs in Prescription Market (2008 & 2009)
Figure 4-2: Generic Drugs Market (Billion US$) 2009-2013
Figure 4-3: Share of Generic and Branded Drugs in Pharma Market (By Sales Value), 2009
Figure 4-4: Share of Generic and Branded Drugs in Prescription Market (By Sales Volume), 2009
Figure 6-1: Generic Drugs Approval Process
Figure 7-1: US - Biogenerics Market (Billion US$), 2008 & 2013
Figure 7-2: Forecast for Share of Drugs Type in Biogenerics Market (2016)
LIST OF TABLES:
Table 5-1: Top Therapeutic Categories by Sales (Billion US$), 2009
Table 5-2: Patent Expiry of Key Lipid Regulators
Table 5-3: Patent Expiry of Key Antipsychotic Drugs
Table 5-4: Patent Expiration of Key Angiotensin II Receptor
Table 5-5: Patent Expiration of Key Antidepressants Drugs
Table 5-6: Patent Expiration of Key Human Insulin Drugs
Table 5-7: Patent Expiration of Key Proton Pump Inhibitors
Table 7-1: Patent Expiry Dates for Biopharmaceuticals
Table 7-2: Blockbuster Drugs Going Off-patent Globally (2010 to 2012)
Table 8-1: Teva Pharmaceuticals - SWOT Analysis
Table 8-2: Watson pharmaceutical Inc. - SWOT Analysis
Table 8-3: Mylan Inc. - SWOT Analysis
Table 8-4: Pfizer Inc. - SWOT Analysis
Table 8-5: Sandoz Inc. (Novartis) - SWOT Analysis
Table 5-1: Top Therapeutic Categories by Sales (Billion US$), 2009
Table 5-2: Patent Expiry of Key Lipid Regulators
Table 5-3: Patent Expiry of Key Antipsychotic Drugs
Table 5-4: Patent Expiration of Key Angiotensin II Receptor
Table 5-5: Patent Expiration of Key Antidepressants Drugs
Table 5-6: Patent Expiration of Key Human Insulin Drugs
Table 5-7: Patent Expiration of Key Proton Pump Inhibitors
Table 7-1: Patent Expiry Dates for Biopharmaceuticals
Table 7-2: Blockbuster Drugs Going Off-patent Globally (2010 to 2012)
Table 8-1: Teva Pharmaceuticals - SWOT Analysis
Table 8-2: Watson pharmaceutical Inc. - SWOT Analysis
Table 8-3: Mylan Inc. - SWOT Analysis
Table 8-4: Pfizer Inc. - SWOT Analysis
Table 8-5: Sandoz Inc. (Novartis) - SWOT Analysis
